- Home
- CDE vs HCM Comparison
CDE vs HCM Comparison
Compare CDE & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDE
- HCM
- Stock Information
- Founded
- CDE 1928
- HCM 2000
- Country
- CDE United States
- HCM Hong Kong
- Employees
- CDE N/A
- HCM N/A
- Industry
- CDE Precious Metals
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- CDE Basic Materials
- HCM Health Care
- Exchange
- CDE Nasdaq
- HCM Nasdaq
- Market Cap
- CDE 2.4B
- HCM 2.5B
- IPO Year
- CDE N/A
- HCM N/A
- Fundamental
- Price
- CDE $7.84
- HCM $14.21
- Analyst Decision
- CDE Strong Buy
- HCM Hold
- Analyst Count
- CDE 4
- HCM 1
- Target Price
- CDE $8.00
- HCM $19.00
- AVG Volume (30 Days)
- CDE 16.6M
- HCM 82.7K
- Earning Date
- CDE 05-07-2025
- HCM 03-19-2025
- Dividend Yield
- CDE N/A
- HCM N/A
- EPS Growth
- CDE N/A
- HCM N/A
- EPS
- CDE 0.27
- HCM 0.04
- Revenue
- CDE $1,201,008,000.00
- HCM $630,201,000.00
- Revenue This Year
- CDE $53.22
- HCM $14.86
- Revenue Next Year
- CDE $7.37
- HCM $19.54
- P/E Ratio
- CDE $28.58
- HCM $68.70
- Revenue Growth
- CDE 41.80
- HCM N/A
- 52 Week Low
- CDE $4.57
- HCM $11.51
- 52 Week High
- CDE $7.72
- HCM $21.92
- Technical
- Relative Strength Index (RSI)
- CDE 75.04
- HCM 45.83
- Support Level
- CDE $5.21
- HCM $14.18
- Resistance Level
- CDE $5.51
- HCM $14.84
- Average True Range (ATR)
- CDE 0.35
- HCM 0.57
- MACD
- CDE 0.19
- HCM -0.03
- Stochastic Oscillator
- CDE 99.43
- HCM 1.94
About CDE Coeur Mining Inc.
Coeur Mining Inc is a metals producer focused on mining precious minerals in the Americas. It is involved in the discovery and mining of gold and silver and generates the vast majority of revenue from the sale of these precious metals. The operating mines of the company are palmarejo, Rochester, Wharf, and Kensington. Its projects are located in the United States, Canada Mexico, and North America.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.